rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Tvardi Therapeutics, Inc.

TVRD · Nasdaq

Health CareBiotechnologyNot moving yet

TVRD stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 60.5% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
58 (-6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$5,110$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders58-6 on the quarter
New · exited14 · 22
Reported value$4.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Slate Path Capital LPunchanged · filed 14 Aug 2026704,118$1.3M00.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026344,382$654K-326−0.1%
AMERICAN FINANCIAL GROUP INCunchanged · filed 12 Aug 2026223,659$425K00.0%
UBS Group AGadded · filed 13 Aug 2026111,133$211K+60,679+120.3%
SILVERCREST ASSET MANAGEMENT GROUP LLCunchanged · filed 14 Aug 2026101,034$192K00.0%
BlackRock, Inc.reduced · filed 7 Aug 202695,478$181K-292,597−75.4%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 202691,409$174K-691−0.8%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202690,350$172K-91,989−50.4%
MORGAN STANLEYadded · filed 13 Aug 202677,845$148K+4,951+6.8%
Duncan Williams Asset Management, LLCunchanged · filed 22 Jul 202663,241$120K00.0%
31 Mar 2023 – 30 Jun 2026
33362Mar 23Sep 23Sep 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Cynthia Smith Company insiderDirector · last 9 Jun 20260 · 0
Michael S. Wyzga Company insiderDirector · last 9 Jun 20260 · 0
Sujal Shah Company insiderDirector · last 9 Jun 20260 · 0
Susan Shiff Company insiderDirector · last 9 Jun 20260 · 0
Wallace L. Hall Jr. Company insiderDirector · last 9 Jun 20260 · 0
Avi Daniel Conn Company insiderChief Financial Officer · last 29 Jan 20260 · 0
Imran Nizamudin Alibhai Company insiderChief Executive Officer · last 29 Jan 20260 · 0
John Saewook Kauh Company insiderChief Medical Officer · last 29 Jan 20260 · 0
Stephen Paul O'Brien Company insiderPrincipal Accounting Officer · last 29 Jan 20260 · 0
Samuel David Tweardy Company insider10% owner · last 7 Jul 20250 · 0
Jeffrey Leroy Larson Company insiderSVP, Research & Development · last 17 Apr 20250 · 0
Shaheen Wirk Company insiderDirector · last 17 Apr 20250 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-127%
Share count trendFY 2025 · to 26 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$20.7M

Analyst forecasts

No analyst forecasts yet.